Alnylam Reinforces Vutrisiran's Lead in ATTR-CM with New ESC Data
Event summary
- Alnylam presented new data at ESC Congress 2026 showing vutrisiran's consistent benefits across ATTR-CM patient populations, including those on tafamidis.
- HELIOS-B subgroup analysis demonstrated vutrisiran's clinical efficacy regardless of baseline tafamidis use, with similar mortality and cardiovascular outcomes.
- Zilebesiran data suggests potential for biannual dosing in uncontrolled hypertension, with significant SBP reductions observed in high-risk patients.
- Pooled Phase 3 data confirmed consistent treatment effects of RNAi-powered TTR silencing across sexes in ATTR-CM and hATTR-PN.
The big picture
Alnylam's ESC 2026 data reinforces its leadership in RNAi therapeutics for cardiovascular diseases, particularly in ATTR-CM. The findings position vutrisiran as a versatile treatment option across diverse patient populations and treatment settings, while zilebesiran's potential in hypertension could open a significant new market. The company's ability to leverage RNAi technology across multiple cardiovascular indications highlights its strategic focus on high-unmet-need diseases.
What we're watching
- Therapeutic Positioning
- Whether vutrisiran can solidify its position as a first-line treatment for ATTR-CM, particularly in combination with stabilizers like tafamidis.
- Hypertension Market Expansion
- The pace at which zilebesiran advances through Phase 3 trials and its potential to disrupt the uncontrolled hypertension treatment landscape.
- Regulatory Pathways
- How Alnylam navigates regulatory approvals for expanded indications and combination therapies across global markets.